DF up +13.31% percent right now. $DF High is at 16.60 and

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 1:04 PM

DF up +13.31% percent right now. $DF High is at 16.60 and the Low 15.73 with current volume of 6,182,752.

Recent News posted below.

DF Dean Foods Company Recent Headline News

Why Now Is the Best Time for Investors to Bite Into Dean Foods
at The Street - 51 mins ago
Shares are trading at median target of $16.50, suggesting they're heading towards $22 -- their high analysts' 12-month price target, which calls for gains of around 37%.
WWAV: 35.70 (-1.23), SPY: 203.76 (+0.42), MDLZ: 37.66 (-0.10), CAG: 34.53 (-0.09), DF: 16.41 (+1.99)

WhiteWave Q3 Tops On Acquisitions, But Guides Q4 Low
at Investor's Business Daily - 2 hrs 13 mins ago
WhiteWave Foods' (WWAV) shares fell Monday despite a strong third quarter as the premium and organic packaged products maker issued weak guidance for the fourth quarter. WhiteWave, which was spun off from Dean Foods (DF) in 2012, reported a 42% jump...
WWAV: 35.70 (-1.23), DF: 16.41 (+1.99)

Stocks Mixed In Quiet Open; Dean Foods Tops Expectations
at Investor's Business Daily - 2 hrs 18 mins ago
Stocks loitered near their starting levels early Monday, with little news or economic data to stir the session. The Nasdaq eked up 0.1%. The Dow Jones industrial average and the S&P 500 were essentially flat. Volume was quiet in the stock market...
VIPS: 24.47 (+1.13), ARRS: 30.60 (-0.24), DF: 16.41 (+1.99), CMCSA: 52.82 (-2.33), TOL: 33.35 (+1.13)

Dean Foods Stock Soars As Dairy Giant Sees Q4 Profit
at Investor's Business Daily - 2 hrs 29 mins ago
Dean Foods (DF) topped analysts' third-quarter estimates and offered bullish guidance, driving its shares up 12% in early trading Monday. The biggest U.S. milk producer, parent of Alta Dena, Berkeley Farms and TruMoo branded products, reported a...
WWAV: 35.70 (-1.23), DF: 16.41 (+1.99)

Dean Foods (DF) Stock Is Higher Today After Earnings Beat
at The Street - Mon Nov 10, 9:03AM CST
Dean Foods (DF) is gaining Monday after beating analysts' estimates for earnings in the third quarter.
DF: 16.41 (+1.99)

Premarket: Stock Futures Mixed; Gilead Climbs On Merck News
at Investor's Business Daily - Mon Nov 10, 7:59AM CST
Stock futures shifted from thin, early losses to mixed trade ahead of Monday's open. Nasdaq 100 futures shed losses and were up a narrow 3.5 points. Dow futures remained 2.9 points below fair market value. S&P 500 futures were flat. The stock market...
WWAV: 35.70 (-1.23), GOGO: 15.45 (-1.19), GILD: 107.13 (+0.68), MRK: 59.04 (-0.30), CMCM: 20.83 (+0.63), DF: 16.41 (+1.99)

Dean Foods tops Street 3Q forecasts
Automated Insights - Mon Nov 10, 7:15AM CST
DALLAS (AP) _ Dean Foods Co. (DF) on Monday reported a loss of $16 million in its third quarter.
DF: 16.41 (+1.99)

Dean Foods Reports Third Quarter 2014 Results
PR Newswire - Mon Nov 10, 7:00AM CST
Dean Foods Company (NYSE: DF) today announced third quarter 2014 results.
DF: 16.41 (+1.99)

Will Dean Foods (DF) Q3 Earnings Surprise on Low Costs? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:32PM CST
We expect Dean Foods (DF) to beat expectations when it reports third quarter 2014 results on Nov 10.
KR: 58.36 (+0.56), DLTR: 61.84 (+0.28), BBY: 34.79 (-0.39), DF: 16.41 (+1.99)

Will Demand Media (DMD) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:22PM CST
Demand Media Inc. (DMD) is set to report the third-quarter 2014 results on Nov 10, 2014.
DMD: 6.87 (-0.10), MANU: 15.78 (-0.08), BBY: 34.79 (-0.39), DF: 16.41 (+1.99)

Should You Sell Dean Foods Company (DF) Before Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 7:29AM CST
Investors are always looking for stocks that are poised to beat at earnings season and Dean Foods Company may be one such company.
DF: 16.41 (+1.99)

Will Hain Celestial (HAIN) Q1 Earnings Miss Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 5:55PM CST
Hain Celestial (HAIN) is scheduled to release its first-quarter fiscal 2015 results on Nov 6, 2014.
HAIN: 108.04 (+0.36), LB: 76.05 (+0.44), DIS: 89.18 (-0.82), DF: 16.41 (+1.99)

Will Lions Gate (LGF) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 5:15PM CST
Our proven does not conclusively project Lions Gate Entertainment Corp. (LGF) as likely to beat earnings this quarter.
CST: 39.90 (+0.34), LGF: 34.13 (+0.67), DISCA: 32.29 (-0.33), DF: 16.41 (+1.99)

Will Kate Spade (KATE) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:55PM CST
Kate Spade & Company (KATE) is scheduled to report its third-quarter fiscal 2014 results on Nov 6.
LB: 76.05 (+0.44), KR: 58.36 (+0.56), DF: 16.41 (+1.99), KATE: 30.13 (-0.24)

Downgrade Alert for Dean Foods (DF)
Comtex SmarTrend(R) - Tue Nov 04, 7:09AM CST
Dean Foods (NYSE

F) was downgraded from Equal Weight to Underweight at Stephens today. The stock closed yesterday at $13.95 on volume of 4.1 million shares, above average daily volume of 2.6 million. Potential upside of 18.3% exists for Dean Foods, based on a current level of $13.95 and analysts' average consensus price target of $16.50. The stock should run into initial resistance at its 50-day moving average (MA) of $14.40 and subsequent resistance at its 200-day MA of $15.59.
DF: 16.41 (+1.99)

Will bebe stores (BEBE) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 6:10PM CST
bebe stores inc. (BEBE) is slated to report its first-quarter fiscal 2015 results on Nov 6, 2014.
BEBE: 2.36 (-0.04), LB: 76.05 (+0.44), KR: 58.36 (+0.56), DF: 16.41 (+1.99)

Will News Corp (NWSA) Miss on Earnings This Quarter? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:08PM CST
News Corporation, a diversified media and information services conglomerate, is slated to report first-quarter fiscal 2015 results on Nov 5.
LB: 76.05 (+0.44), DIS: 89.18 (-0.82), DF: 16.41 (+1.99), NWSA: 15.19 (+0.04)

Will Stiff Competition Drag Whole Foods (WFM) Q4 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:01PM CST
Whole Foods (WFM), one of the leading natural and organic foods' supermarkets, is slated to report its fourth-quarter fiscal 2014 results on Nov 5.
WFM: 47.58 (+0.77), LB: 76.05 (+0.44), DIS: 89.18 (-0.82), DF: 16.41 (+1.99)

Packaged Foods and Meats Stocks on our Scanner - Mondelez Intl., Dean Foods, Unilever PLC, Unilever N.V., and Boulder Brands
PR Newswire - Mon Nov 03, 8:30AM CST
Investor-Edge has initiated coverage on the following equities: Mondelez International Inc. (NASDAQ: MDLZ), Dean Foods Company (NYSE: DF), Unilever PLC (NYSE: UL), Unilever N.V. (NYSE: UN), and Boulder Brands Inc. (NASDAQ: BDBD). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 31, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,390.52, up 1.13% and the NASDAQ Composite closed at 4,630.74, up 1.41%. The S&P 500 finished the session 1.17% higher at 2,018.05. During the trading session, all the ten sectors finished on a higher note. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Consumer Staples Sector Index ended the day at 480.90, up 0.68%, with the index advancing 7.60% in the previous three months. Register for your complimentary reports on these five stocks at:
MDLZ: 37.66 (-0.10), UN: 38.92 (+0.39), BDBD: 9.05 (+0.29), UL: 40.39 (+0.41), DF: 16.41 (+1.99)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Innovent's IBI3001 Shows Promise in Phase 1 Trials

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

DIRECTV Bags New NHL Deals: Stakes for Sports Fans

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Firefox Champions Privacy with Iconic Internet Campaign

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

CapCut's Role in AI-Assisted Small Biz Marketing

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Ivonescimab Promises New Hope for Advanced BTC Patients

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...